MEDBOT-B's stock surged 5.71% during intraday trading on Thursday, marking a significant upward movement for the medtech company.

The sharp rise appears driven by a confluence of positive corporate developments. The company recently announced a proposed share buyback of up to 10% of its total issued shares, subject to shareholder approval. Concurrently, its board resolved to adopt a new share incentive plan aimed at rewarding contributors to the group.

Further bolstering sentiment, Citibank added MEDBOT-B to its preferred buy list for Hong Kong healthcare stocks, citing that the medtech sector is entering a phase of valuation reassessment. The company also reinforced its technological profile by successfully completing the world's first large-model-based autonomous surgery animal experiment, strengthening long-term growth expectations.